Until the 1990s, venous thromboembolism (VTE) was viewed primarily as a complication of
hospitalization for major surgery (or associated with the late stage of terminal illness) …

ContextAlthough postmenopausal hormone replacement therapy (HRT) is widely used in
the United States, new evidence about its benefits and harms requires reconsideration of its …

Background Reported risk factors for venous thromboembolism (VTE) vary widely, and the
magnitude and independence of each are uncertain. Objectives To identify independent risk …

Background—Oral estrogen therapy increases the risk of venous thromboembolism (VTE) in
postmenopausal women. Transdermal estrogen may be safer. However, currently available …

Menopause is diagnosed after 12 months of amenorrhoea resulting from the permanent
cessation of ovarian function. The mean age at menopause is 51 years. The …

Context Postmenopausal hormone therapy increases the risk of venous thrombosis. It is not
known whether other factors influencing thrombosis add to this risk. Objective To report final …

The incidence of venous thromboembolism exceeds 1 per 1000; over 200,000 new cases
occur in the United States annually. Of these, 30% die within 30 days; one-fifth suffer sudden …

Background Oral oestrogen-replacement therapy (ERT) activates blood coagulation and
increases the risk of venous thromboembolism (VTE) in postmenopausal women …

Background: Oral contraceptive use increases risk for venous thromboembolism, but data on
the effect of postmenopausal hormone therapy are limited. Objective: To determine the effect …

Background: Current use of menopausal hormone therapy (HT) increases the risk of venous
thromboembolism (VTE) and the formulations used may affect risk. Methods: A total of 1 058 …